Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Analysis of Circulating Tumor Markers in the Blood

Next Previous
Trial Profile

Analysis of Circulating Tumor Markers in the Blood

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary) ; Pembrolizumab (Primary) ; Everolimus; Fulvestrant; Palbociclib
  • Indications Advanced breast cancer; Bone cancer; Colorectal cancer; HER2 positive breast cancer; Lung cancer; Non-small cell lung cancer; Sarcoma; Soft tissue sarcoma; Solid tumours; Triple negative breast cancer; Uveal melanoma
  • Focus Biomarker; Proof of concept; Therapeutic Use
  • Acronyms ALCINA

Most Recent Events

  • 30 Sep 2024 Status changed from active, no longer recruiting to completed.
  • 01 Apr 2024 Results assessing the efficacy of fulvestrant and everolimus in CDK4/6i pre-treated mBC patients and circulating tumor DNA (ctDNA) changes throughout therapy, published in the Oncogene
  • 16 Nov 2023 Results assessing prognostic value of three liquid biopsy analytes (CTCs, sEVs, and ctDNA), alone and in combination in patient samples (n=54) from this study published in the British Journal of Cancer.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top